Wrap Text
2021 Annual General Meeting Statement
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
(“Mediclinic”, the “Company”, or the “Group”)
27 July 2021
2021 Annual General Meeting Statement
In line year-to-date operating performance
2021 Annual General Meeting (“AGM”)
Mediclinic, the diversified international private healthcare services group, will today host its
2021 AGM. As explained in the 2021 notice of AGM and following the online shareholder
engagement event on Monday, 19 July 2021, today’s AGM will be purely functional, limited
principally to putting the resolutions to shareholders and calling the poll. There will be no
presentations regarding the Company’s business or current trading and directors based abroad
will not be attending the meeting in person.
In line year-to-date operating performance
Given the strong underlying demand for Mediclinic’s broad range of services across the
continuum of care, the Group continues to expect to deliver growth in revenue and EBITDA
across all three divisions in the financial year ending 31 March 2022 (“FY22”). Year-to-date
operating performance is in line with expectations based on the previously disclosed FY22
guidance. In FY22, pre-COVID-19 seasonal trends which impact operating performance are
expected to return and be reflected in the half-year results of Hirslanden and Mediclinic Middle
East.
With the ongoing pandemic, varied pace of vaccine rollouts and planning assumptions of further
waves and variants causing continued uncertainty on the shape of the recovery, Mediclinic
remains cautious as to the full impact of COVID-19 on near-term operating performance. In line
with the outlook statement provided as part of the 2021 financial year results, and given the
Group’s focus on operational and cost efficiencies, it does not anticipate any long-term
structural impediments in returning EBITDA margins at Hirslanden and Mediclinic Southern
Africa to pre-pandemic levels. At Mediclinic Middle East, the Group expects margins to continue
to gradually increase as it grows its presence across the region, supported by recent expansion
and upgrade projects in Dubai and Abu Dhabi.
Cautionary Statement
This announcement contains certain forward-looking statements relating to the business of the
Company and its subsidiaries, including with respect to the progress, timing and completion of
the Group’s development; the Group’s ability to treat, attract and retain patients and clients; its
ability to engage consultants and healthcare practitioners and to operate its business and
increase referrals; the integration of prior acquisitions; the Group’s estimates for future
performance and its estimates regarding anticipated operating results; future revenue; capital
requirements; shareholder structure; and financing. In addition, even if the Group’s actual
results or development are consistent with the forward-looking statements contained in this
announcement, those results or developments may not be indicative of the Group’s results or
developments in the future. In some cases, forward-looking statements can be identified by
words such as “could”, “should”, “may”, “expects”, “aims”, “targets”, “anticipates”, “believes”,
“intends”, “estimates”, or similar. These forward-looking statements are based largely on the
Group’s current expectations as of the date of this announcement and are subject to a number
of known and unknown risks and uncertainties and other factors that may cause actual results,
performance or achievements to be materially different from any future results, performance or
achievement expressed or implied by these forward-looking statements. In particular, the
Group’s expectations could be affected by, among other things, uncertainties involved in the
integration of acquisitions or new developments; changes in legislation or the regulatory regime
governing healthcare in Switzerland, South Africa, Namibia and the UAE; poor performance by
healthcare practitioners who practise at its facilities; unexpected regulatory actions or
suspensions; competition in general; the impact of global economic changes; the impact of
pandemics, including COVID-19; and the Group’s ability to obtain or maintain accreditation or
approval for its facilities or service lines. In light of these risks and uncertainties, there can be
no assurance that the forward-looking statements made in this announcement will in fact be
realised and no representation or warranty is given as to the completeness or accuracy of the
forward-looking statements contained in this announcement.
The Group is providing the information in this announcement as of this date, and disclaims any
intention to, and makes no undertaking to, publicly update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise.
About Mediclinic International plc
Mediclinic is a diversified international private healthcare services group, established in South
Africa in 1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and
the United Arab Emirates (“UAE”).
The Group’s core purpose is to enhance the quality of life.
Its vision is to be the partner of choice that people trust for all their healthcare needs.
Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the
continuum of care in such a way that the Group will be regarded as the most respected and
trusted provider of healthcare services by patients, medical practitioners, funders and
regulators of healthcare in each of its markets.
At 31 March 2021, Mediclinic comprised 74 hospitals, five subacute hospitals, two mental health
facilities, 18 day case clinics and 18 outpatient clinics. Hirslanden operated 17 hospitals and
four day case clinics in Switzerland with more than 1 900 inpatient beds; Mediclinic Southern
Africa operations included 50 hospitals (three of which in Namibia), five sub-acute hospitals,
two mental health facilities and 12 day case clinics (four of which operated by Intercare) across
South Africa, and around 8 600 inpatient beds; and Mediclinic Middle East operated seven
hospitals, two day case clinics and 18 outpatient clinics with more than 900 inpatient beds in
the UAE. In addition, under management contracts, Mediclinic Middle East operates one
hospital in Abu Dhabi and will open a 200-bed hospital in the Kingdom of Saudi Arabia in mid-
2022.
The Company’s primary listing is on the London Stock Exchange (“LSE”) in the United
Kingdom, with secondary listings on the JSE in South Africa and the Namibian Stock Exchange
in Namibia.
Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private
healthcare group based in the United Kingdom and listed on the LSE.
For further information, please contact:
Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181
Media queries
FTI Consulting
Ben Atwell/Ciara Martin – UK
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000
Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Corporate broker: Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd
Date: 27-07-2021 08:00:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
Sharenet Sites 
